What is Braftovi used to treat?
Medically reviewed by Judith Stewart, BPharm. Last updated on June 2, 2020.
Braftovi is an oral small molecule BRAF kinase inhibitor.
Braftovi (encorafenib) is used in combination with Mektovi (binimetinib) for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.
Roughly 50% of patients diagnosed with metastatic melanoma test positive for the BRAF mutation, and it is the most common genetic mutation in metastatic melanoma.
Braftovi is not indicated for the treatment of patients with wild-type BRAF melanoma.
Braftovi is used in combination with Erbitux (cetuximab), for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy.
BRAF mutations are estimated to occur in up to 15% of people with metastatic colorectal cancer.
Braftovi is not indicated for treatment of patients with wild-type BRAF CRC.
Related Medical Questions
- What type of drug is Libtayo?
- How does Odomzo work?
- What is Mektovi used to treat?
- What is the difference between Opdivo and Keytruda?
- Pembrolizumab vs. nivolumab: how do they compare?
- What happens when you stop taking Opdivo for melanoma?
- What is the cost of Tecentriq?
- What type of cancer is Tecentriq used to treat?